Although the activation of TRPM2 by ROS in tumor cells is not desirable due to its cell survival-promoting effects, it suggests that pharmacological inhibition of TRPM2 in cancer could be a novel and highly promising therapeutic approach. Here, TRPM2 is linked to neoplasm.